百济神州:光环之下,荆棘丛生

妙投APP
26 Dec 2024

出品 | 妙投APP作者 | 张贝贝头图 | 视觉中国近期,高瓴资本竟然减持了其“偏爱”的百济神州。这还是蛮令人惊讶的,毕竟从百济神州A轮融资开始,高瓴资本多轮领投,是陪伴百济神州从起步到美国纳斯达克、香港联交所和上交所科创板三地上市的机构。那么,高瓴资本减持百济神州的原因是什么?经过分析,虽然百济神州有多个光环,如创新实力较强,拥有国内首款年销售额超十亿美元的重磅新药泽布替尼;且凭借产品较好销售...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10